208 related articles for article (PubMed ID: 15160855)
1. The rationale for and background of radioimmunotherapy: an emerging therapy for B-cell non-Hodgkin's lymphoma.
Riley MB; Byar K
Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):1-7. PubMed ID: 15160855
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Riley MB; Gordon LI
Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):8-13. PubMed ID: 15160856
[TBL] [Abstract][Full Text] [Related]
3. Educating patients about radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Byar K
Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):20-5. PubMed ID: 15160858
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
Juweid ME
J Nucl Med; 2002 Nov; 43(11):1507-29. PubMed ID: 12411555
[TBL] [Abstract][Full Text] [Related]
5. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma.
Witzig TE
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S91-5. PubMed ID: 11587375
[TBL] [Abstract][Full Text] [Related]
6. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
7. Future directions in radioimmunotherapy for B-cell lymphoma.
Horning SJ
Semin Oncol; 2003 Dec; 30(6 Suppl 17):29-34. PubMed ID: 14710401
[TBL] [Abstract][Full Text] [Related]
8. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Gordon LI; Witzig T; Molina A; Czuczman M; Emmanouilides C; Joyce R; Vo K; Theuer C; Pohlman B; Bartlett N; Wiseman G; Darif M; White C
Clin Lymphoma; 2004 Sep; 5(2):98-101. PubMed ID: 15453924
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Witzig TE; Gordon LI; Cabanillas F; Czuczman MS; Emmanouilides C; Joyce R; Pohlman BL; Bartlett NL; Wiseman GA; Padre N; Grillo-López AJ; Multani P; White CA
J Clin Oncol; 2002 May; 20(10):2453-63. PubMed ID: 12011122
[TBL] [Abstract][Full Text] [Related]
10. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).
Hernandez MC; Knox SJ
Semin Oncol; 2003 Dec; 30(6 Suppl 17):6-10. PubMed ID: 14710397
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunotherapy for NHL: experience of 90Y-ibritumomab tiuxetan in clinical practice.
Hagenbeek A
Leuk Lymphoma; 2003; 44 Suppl 4():S37-47. PubMed ID: 15154741
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Alcindor T; Witzig TE
Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
[TBL] [Abstract][Full Text] [Related]
13. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
de Nully Brown P; Jurlander J; Lindén O; Hansen M
Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
[TBL] [Abstract][Full Text] [Related]
14. Radiation safety with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy.
Hendrix C
Semin Oncol Nurs; 2004 Feb; 20(1 Suppl 1):14-9. PubMed ID: 15160857
[TBL] [Abstract][Full Text] [Related]
15. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma.
Witzig TE
Drugs Today (Barc); 2004 Feb; 40(2):111-9. PubMed ID: 15045033
[TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy: a new treatment modality for B-cell non-Hodgkin's lymphoma.
Ghobrial I; Witzig T
Oncology (Williston Park); 2004 May; 18(5):623-30; discussion 633-4, 637-8, 640. PubMed ID: 15209190
[TBL] [Abstract][Full Text] [Related]
17. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
18. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
Hendrix CS; de Leon C; Dillman RO
Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
[TBL] [Abstract][Full Text] [Related]
19. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
Micallef IN
Clin Lymphoma; 2004 Oct; 5 Suppl 1():S27-32. PubMed ID: 15498147
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
Witzig TE
Best Pract Res Clin Haematol; 2006; 19(4):655-68. PubMed ID: 16997175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
